Patents by Inventor Edwin S. Lennox

Edwin S. Lennox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110076293
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Application
    Filed: December 6, 2010
    Publication date: March 31, 2011
    Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
  • Patent number: 7847109
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: December 7, 2010
    Assignee: Pharmagenesis, Inc.
    Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
  • Patent number: 7662976
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: February 16, 2010
    Assignee: Pharmagenesis, Inc.
    Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
  • Publication number: 20090171103
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Application
    Filed: February 5, 2009
    Publication date: July 2, 2009
    Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
  • Patent number: 6991817
    Abstract: An acid-modified arabinogalactan protein composition, having an arabinose-galactaose ratio of less than 3.5:1, comprising 5–10% Rha, 20–35% Gal, and less than 5% Glc, prepared from Astragalus membranaceus, is useful for treating a number of conditions. For example, an acid-modified arabinogalactan protein composition having features of the invention is useful for stimulating hematopolesis, inducing the proliferation of megakaryocytes, inducing the maturation of megakaryocytes, and stimulating the production of IL-1?, IL-6, TNF-?, IFN-?, GM-CSF, G-CSF, and neutrophils, and stimulating the action of neutrophils; stimulating the immune and/or hematopoietic system of a mammal suffering from neutropenia, anemia, thrombocytopenia, exposure to cytotoxic agents, exposure to radiation, cachexia, emesis, and drug withdrawal symptoms; and is effective to restore the immune response to infection, in immunosuppressive conditions, and to protect hepatic cells in hepatitis B.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: January 31, 2006
    Assignee: Pharmagenesis, Inc.
    Inventors: Jinhua An, Karen S. Leu, Edwin S. Lennox, John H. Musser
  • Patent number: 6949510
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: September 27, 2005
    Assignees: Pharmagenesis, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Publication number: 20040235943
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Application
    Filed: June 24, 2004
    Publication date: November 25, 2004
    Inventors: Dongcheng Dai, John H Musser, Edwin S Lennox
  • Publication number: 20030211077
    Abstract: An acid-modified arabinogalactan protein composition, having an arabinose-galactose ratio of less than 3.5:1 or less than 80% of the arabinose:galactose ratio of the arabinogalactan protein component of the composition prior to acid modification, prepared from Astragalus membranaceus, especially from the roots of Atragalus membranaceus, is capable of reconstitution into an aqueous intravenously injectable formulation; and is useful for stimulating hematopoiesis, inducing the proliferation or maturation of megakaryocytes, stimulating the production of IL-1&bgr;, Il-6, TNF-&agr;, IFN-&ggr;, GM-CSF, or G-CSF, stimulating the production or action of neutrophils, treating neutropenia, anemia, or thrombocytopenia, accelerating recovery from exposure (e.g.
    Type: Application
    Filed: November 27, 2002
    Publication date: November 13, 2003
    Inventors: Jinhua An, Karen S. Leu, Edwin S. Lennox, John H. Musser
  • Publication number: 20030206861
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Application
    Filed: May 27, 2003
    Publication date: November 6, 2003
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Patent number: 6599499
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: July 29, 2003
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Pharmagenesis, Inc.
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Publication number: 20030139439
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Application
    Filed: January 10, 2003
    Publication date: July 24, 2003
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Patent number: 6537984
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: March 25, 2003
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Pharmagenesis
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Publication number: 20020016362
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Application
    Filed: June 19, 2001
    Publication date: February 7, 2002
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Patent number: 6294546
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: September 25, 2001
    Assignees: The Broad of Trustees of the Leland Stanford Junior University, Pharmagenesis
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Patent number: 4760026
    Abstract: A monoclonal antibody having specificity for an antigenic determinant of a B-type blood cell. The monoclonal anti-B, produced by a hybridoma cell (the preparation of which is described), affords a defined, specific and cheap blood grouping reagent. The monoclonal antibody is defined by its specificity and functional affinity.
    Type: Grant
    Filed: November 17, 1986
    Date of Patent: July 26, 1988
    Assignee: Celltech Limited
    Inventors: Edwin S. Lennox, Steven H. Sacks